Tunlametinib
3 abstracts
Abstract
Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.Org: The Comprehensive Cancer Center of Drum-Tower Hospital, The Third People's Hospital of Zhengzhou, The First Affiliated Hospital of Dalian Medical University,
Abstract
A phase III, open-label, multicenter, randomized controlled trial of tunlametinib versus investigator-selected chemotherapy in patients with advanced NRAS-mutant melanoma who had previously received immunotherapy.Org: Drum-Tower Hospital,
Abstract
A phase II study of tunlametinib in combination with vemurafenib in patients with BRAF V600-mutant advanced melanoma.Org: Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated hospital of Medical School, Nanjing University., Nanjing, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Department of Head and Neck and Rare Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China, Shanghai Kechow Pharma, Shanghai, China,